Newsfeeds Archive - Spark Newswire

2 minute read

Fusion Pharmaceuticals Announces First Patient Dosed In The Phase 2 Portion Of The AlphaBreak Trial Evaluating FPI-2265 In Metastatic Castration-Resistant Prostate Cancer

May 9, 5:28 PM

AlphaBreak is a Phase 2/3 registrational program for FPI-2265 in patients with metastatic castration-resistant prostate cancerHAMILTON, ON and BOSTON, May 9, 2024 /CNW/ -- Fusion Pharmaceuticals Inc. (NASDAQ:FUSN),

FUSN

2 minute read

Top 4 Health Care Stocks That May Plunge This Month

By Avi Kapoor

April 26, 8:09 AM

As of April 26, 2024, four stocks in the health care sector could be flashing a real warning…

AZN

2 minute read

AstraZeneca, Through A Subsidiary, Will Acquire All Of Fusion’s Outstanding Shares For A Price Of $21.00 Per Share In Cash At Closing Plus A Non-Transferable CVR Representing The Contingent Right To Receive $3.00/Share In Cash Payable Upon The Achievem…

By Benzinga Newsdesk

April 25, 5:12 PM

Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radioconjucates (RCs) as precision medicines, today announced that it has filed and is in the process of

AZN

2 minute read

AstraZeneca Hikes Annual Dividend By 7% Just Before Vote On Its CEO’s Pay Package Boost

By Vandana Singh

April 11, 9:04 AM

AstraZeneca boosts its 2024 dividend to $3.10/share, reflecting confidence in performance. Shareholder concerns addressed as CEO compensation proposal approaches vote. Recent acquisitions and FDA approvals signal growth.

AZN

2 minute read

AstraZeneca CEO Highlights Decade-Long Sales Goal Of $45B Along With Investor Doubts As It Lags In Weight Loss Race

By Vandana Singh

April 2, 2:54 PM

AstraZeneca's CEO Pascal Soriot celebrates hitting a $45 billion sales target set a decade ago despite initial skepticism. Investor confidence remains a challenge amid stagnant shares and concerns over future growth. Soriot's strategic overhaul focuses on R&D and acquisitions.

AZN

2 minute read

Fusion Pharmaceuticals Enters Into Exclusive Worldwide License Agreement With Heidelberg University And Euratom For Actinium-Based PSMA Targeted Radiotherapy

By Benzinga Newsdesk

February 16, 9:45 AM

FPI-2265 positioned to be the first approved PSMA targeted alpha therapyHAMILTON, ON and BOSTON, Feb. 16, 2024 /CNW/ -- Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on

FUSN

3 minute read

Analyst Ratings

Expert Outlook: Fusion Pharmaceuticals Through The Eyes Of 6 Analysts

By Benzinga Insights

January 26, 10:00 AM

6 analysts have shared their evaluations of Fusion Pharmaceuticals (NASDAQ:FUSN) during the recent three months, expressing a mix…

FUSN

1 minute read

Movers

12 Health Care Stocks Moving In Friday’s After-Market Session

By Benzinga Insights

January 19, 5:31 PM

Gainers Talphera (NASDAQ:TLPH) stock increased by 10.2% to $0.97 during Friday’s after-market session. The company’s market cap stands…

ADIL

3 minute read

Why Dermata Therapeutics Shares Are Trading Higher By Over 57%; Here Are 20 Stocks Moving Premarket

By Avi Kapoor

January 5, 9:03 AM

Shares of Dermata Therapeutics, Inc. (NASDAQ: DRMA) rose sharply in pre-market trading after the company announced the issuance of a new patent in Japan for its DMT410 program for the treatment of hyperhidrosis. Dermata Therapeutics shares jumped 57.3% to $0.9601 in pre-market trading.

AIMD

2 minute read

Rivian Automotive Reports Weak Delivery Figures, Joins JOYY, MiMedx Group And Other Big Stocks Moving Lower On Tuesday

By Avi Kapoor

January 2, 12:47 PM

U.S. stocks traded mostly lower, with the Nasdaq Composite falling around 200 points on Tuesday.

AMPX